3SBio reports interim results. Juyuan sets HKD 30.40 target for 3SBio stock

Published on 10/07/2026 at 06:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted operating net profit rose 26.50 percent in the first half of 2026. 3SBio stock is valued at HKD 38.8 billion.

3SBio, KYG8875G1029, Illustration mit AI erstellt.

3SBio (ISIN KYG8875G1029) reported its first-half 2026 results on September 30, 2026, with revenue of RMB 4.53 billion, up 3.90 percent year over year, while Juyuan Research set a HKD 30.40 target for the stock on September 23, 2026. Moomoo carried the interim figures, and Futunn published the analyst target.

Revenue growth hides a split

Revenue increased 3.90 percent in the six months ended June 30, 2026, but the mix shifted sharply. Biological product sales fell 19.30 percent to RMB 3.44 billion, while CDMO revenue jumped 160.90 percent to RMB 230.00 million, according to Moomoo.

The licensing contribution was also material at RMB 850.00 million. That combination explains why headline revenue grew even as the established biologics portfolio contracted during the reporting period.

Profit quality becomes the test

Net profit attributable to equity shareholders declined 15.60 percent to RMB 1.15 billion in the first half of 2026, while adjusted operating net profit rose 26.50 percent to RMB 1.44 billion, Moomoo reported. The divergence puts greater weight on licensing income, cost control and the conversion of research spending into commercial products.

Research and development expenses rose 24.90 percent to RMB 680.00 million, equal to 15.10 percent of revenue. The report also identified medical insurance reform, centralized procurement and exchange-rate movements as risks for the second half of 2026.

Analyst target leaves room for execution

Juyuan Research initiated coverage with a Buy rating and a HKD 30.40 target on September 23, 2026, according to Futunn. Its forecast called for 2026 revenue of RMB 9.01 billion, down 49.00 percent year over year, followed by growth of 2.00 percent in 2027 and 9.00 percent in 2028.

The investment case therefore rests on pipeline progress and the ability to replace pressure on mature biologics with licensing, CDMO expansion and new product launches. That is a more demanding setup than the 3.90 percent first-half revenue increase alone suggests.

Market value and trading context

The last Lang & Schwarz prior close was EUR 1.81 on October 5, 2026. On the Hong Kong Stock Exchange, 3SBio was trading at HKD 15.53 at 11:45 a.m. HKT on October 7, 2026, versus a prior close of HKD 16.01; its market capitalization was HKD 38.8 billion on the same date, and the 52-week range was HKD 14.81 to HKD 35.42.

The further course of trading is shown by the continuously updated real-time quote of 3SBio stock.